Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia-Reference-Cited by-同舟云学术

Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

Published:2010-06-17 Issue:24 Volume:362 Page:2260-2270
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Kantarjian Hagop,Shah Neil P.,Hochhaus Andreas,Cortes Jorge,Shah Sandip,Ayala Manuel,Moiraghi Beatriz,Shen Zhixiang,Mayer Jiri,Pasquini Ricardo,Nakamae Hirohisa,Huguet Françoise,Boqué Concepción,Chuah Charles,Bleickardt Eric,Bradley-Garelik M. Brigid,Zhu Chao,Szatrowski Ted,Shapiro David,Baccarani Michele

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa1002315

Cited by 1334 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cancer Patient-Derived Cell-Based Models: Applications and Challenges in Functional Precision Medicine;Life;2024-09-10

2. FDA-approved small molecule kinase inhibitors for cancer treatment (2001–2015): Medical indication, structural optimization, and binding mode Part I;Bioorganic & Medicinal Chemistry;2024-09

3. Choosing the Best Firstline Drug: Does Efficacy Make You Think About Cost?;Clinical Lymphoma Myeloma and Leukemia;2024-09

4. [Artículo traducido] Asciminib para el tratamiento de la leucemia mieloide crónica en tercera línea: análisis coste-efectividad basado en el enfoque de remisión libre de tratamiento;Farmacia Hospitalaria;2024-09

5. Asciminib for third-line treatment of chronic myeloid leukemia: Cost-effectiveness analysis based on treatment-free remission approach;Farmacia Hospitalaria;2024-09